Captopril and Hypertension Development in the SHR

Jf, Giudicelli; Freslon, Jean‐Louis; Glasson, S.S.; Richer, Christine

doi:10.3109/10641968009037162

Cited by 86 publications

(57 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,12 Studies from the group of Berecek suggested that these results could result from a decrease in AVP levels. 13,14 Similar studies have been performed by other laboratories using both ACE inhibitors, 15,16 and angiotensin receptor blockers (ARBs). 17,18 In our initial studies, we found that treatment of stroke-prone SHR with an ACE inhibitor from age 3-10 weeks resulted in a sustained suppression of blood pressure, whereas such an effect was not found with the vasodilator hydralazine.…”

Section: Animal Models Of Hypertension Preventionsupporting

confidence: 51%

Prevention and regression of hypertension: role of renal microvascular protection

et al. 2009

View full text Add to dashboard Cite

Hypertension is a disease which affects over 26.4% of the world adult population, therefore novel approaches to the prevention and treatment of this disease need to be examined. Previous studies from our and other laboratories have shown that treatment of spontaneously hypertensive rats (SHR) and Dahl salt-sensitive rats with a renin-angiotensin system (RAS) inhibitor during the 'critical period' in hypertension development results in prevention of the later development of hypertension. In humans, Julius et al. reported similar findings in the landmark TROPHY study. Recently, we reported that 'pulse' treatment of SHR with highdose angiotensin receptor blocker (ARB) is effective in causing sustained reduction of already established hypertension, even when the treatment was started after the 'critical period'. These results suggest the possibility that 'regression' of established hypertension may become feasible, and we have started a prospective, multicenter clinical study (STAR CAST study) to examine this possibility. In our animal studies, we found that treatment of rats during the 'critical period' with an ARB inhibits the development of renal arteriolar hypertrophy. Moreover, a high-dose angiotensin blocker caused a remarkable reversal of renal arteriolar hypertrophy in SHR, which was associated with changes in microvascular MMP expression. These results suggest that changes in the renal microvasculature may have an important role in the mechanisms of hypertension prevention and regression by ARB.

show abstract

Section: Animal Models Of Hypertension Preventionsupporting

confidence: 51%

Prevention and regression of hypertension: role of renal microvascular protection

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Studies from the group of Berecek et al suggested that these results could result from a decrease in arginine vasopressin (AVP) levels (Lee et al, 1991), (Zhang et al, 1996). Similar findings have been reported by other laboratories, using both ACE inhibitors (Giudicelli et al, 1980), (Christensen et al, 1989) and ARBs (Morton et al, 1992), (Gillies et al, 1997).…”

Section: Prevention Of Hypertensionsupporting

confidence: 75%

Prevention and Regression of Chronic Kidney Disease and Hypertension

Sasamura¹

2012

Chronic Kidney Disease

View full text Add to dashboard Cite

“…The first observation on ACE inhibitors and vascular structure goes back to 1980 when Giudicelli et al 27 administered captopril, atenolol, or hydralazine to young (6-week-old) spontaneously hypertensive rats for 14 weeks. These authors reported that captopril almost completely prevented the development of hypertension as did atenolol and hydralazine.…”

Section: Resistance Arteriesmentioning

confidence: 99%

The potential role of angiotensin II in the vasculature

Levy

1998

J Hum Hypertens

View full text Add to dashboard Cite

Arterial hypertension is associated with marked changes in the structure of both resistance and large arteries. The renin-angiotensin system is largely involved in these alterations; chronic blockade of the renin-angiotensin system prevents and/or reverses most of the alterations of the vasculature in experimental and clinical hypertension. In this review we have analysed the differential role of AT 1 and AT 2 receptors in the response of the vessels to arterial hypertension. It emerges that the relative involvement of each receptor

show abstract

Captopril and Hypertension Development in the SHR

Cited by 86 publications

References 22 publications

Prevention and regression of hypertension: role of renal microvascular protection

Prevention and regression of hypertension: role of renal microvascular protection

Prevention and Regression of Chronic Kidney Disease and Hypertension

The potential role of angiotensin II in the vasculature

Contact Info

Product

Resources

About